Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer

Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer

The purpose was to explore potential biomarkers of the efficacy and toxicity of triple therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer (MBC). Tumor tissues before treatment and blood samples at pretreatment, during and after treatment were col...

Full description

Bibliographic Details
Main Authors: Yukinori Ozaki, Junji Tsurutani, Toru Mukohara, Tsutomu Iwasa, Masato Takahashi, Yuko Tanabe, Hidetaka Kawabata, Norikazu Masuda, Manabu Futamura, Hironobu Minami, Koji Matsumoto, Kenichi Yoshimura, Shigehisa Kitano, Toshimi Takano
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Data in Brief
Subjects:
Nivolumab
Bevacizumab
Immunotherapy
PD-L1
VEGF
Metastatic breast cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S235234092200765X

Internet

http://www.sciencedirect.com/science/article/pii/S235234092200765X

Similar Items